EUCTR2014-005685-30-GB进行中（未招募）1 期
ong-term safety and efficacy study of Ferriprox® for the treatment of transfusional iron overload in patients with sickle cell disease or other anemias. - FIRST (Ferriprox in patients with iron overload in sickle cell disease trial)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Completed study LA38-0411.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Plan to participate in another clinical trial at any time from the day of enrollment until 30 days post-treatment in the current study.
- •2. For only those patients who were treated with deferoxamine in study LA38-0411 (Group 2): Presence of any medical condition (including clinically significant laboratory abnormalities, such as ALT = 5 x ULN or creatinine = 2 x ULN), psychological condition, or psychiatric condition which in the opinion of the investigator would cause participation in the study to be unwise.
- •3. Pregnant, breastfeeding, or planning to become pregnant during the study period.
- •4. Treatment failure after 1 year on deferiprone which in the investigator’s judgment indicates the need for the patient to be started on a different iron chelator.
研究者
相似试验
进行中（未招募）
1 期
A study of a drug (Ferriprox®) that removes extra iron from the body, to see how safe it is and how well it works in patients with sickle cell disease or other anaemiasEUCTR2013-002181-39-GBApoPharma Inc.300
进行中（未招募）
1 期
An international open label trial of deferiprone in patients with iron storage brain disorders - an extension to TIRCON2012V1 (a randomised controlled trial of deferiprone in patients with iron storage brain disorders).EUCTR2014-001427-79-GBApoPharma Inc89
进行中（未招募）
1 期
An 18-month extension of an international trial of deferiprone in patients with iron storage brain disordersEUCTR2014-001427-79-DEApoPharma Inc.90
进行中（未招募）
1 期
An 18-month extension of an international trial of deferiprone in patients with iron storage brain disordersPantothenate Kinase-Associated Neurodegeneration (PKAN)MedDRA version: 21.1Level: PTClassification code 10053643Term: Neurodegenerative disorderSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001427-79-ITAPOTEX EUROPE B.V.68
已完成
不适用
The efficacy and safety of FOLFOXIRI for unresectable advanced rectal cancer : a prospective observational studyJPRN-UMIN000040275Kanagawa Cancer Center20